{"id":"amg-386-with-or-without-trastuzumab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201585","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting angiogenesis, AMG 386 aims to reduce the growth of new blood vessels that supply tumors, thereby slowing tumor growth. This mechanism is particularly relevant in the context of cancer treatment, where tumor angiogenesis is a key factor in tumor progression. The addition of Trastuzumab, a monoclonal antibody targeting the HER2 receptor, may enhance the anti-tumor effects of AMG 386 by targeting a different pathway involved in tumor growth and survival.","oneSentence":"AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:49.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, HER2-positive"}]},"trialDetails":[{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15841,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMG 386 (Trebananib); (Trastuzumab) Herceptin"],"phase":"phase_2","status":"active","brandName":"AMG 386 with or without Trastuzumab","genericName":"AMG 386 with or without Trastuzumab","companyName":"QuantumLeap Healthcare Collaborative","companyId":"quantumleap-healthcare-collaborative","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis. Used for Metastatic breast cancer, HER2-positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}